Home
About BioDiem
Company Overview
Board & Management
Technology
LAIV
BDM-E
BDM-I
Partnering
Corporate Partners
Licensing
Investor Relations
Financial Reports
Corporate Governance
Corporate Directory
Contact Us
Contact Us
Name
*
Email
*
Company Name
Subject
*
Message
*
Type of Enquiry
This is a General Enquiry
Receive Annual Report via Email
Receive ASX Announcements via Email
Type the characters you see in the picture below
BioDiem Ltd
Level 10, South Tower
459 Collins Street
Melbourne Victoria 3000
Telephone:
+ 61 3 9613 4100
Facsimile: + 61 3 9613 4111
E-mail:
info@biodiem.com
Van Leeuwenhoeck Institute initiates coverage on BioDiem (ASX: BDM)
BioDiem Licenses LAIV Technology
Appendix 4C - Quarterly Update
New issue announcement
BioDiem acquires Savine Therapeutics Pty Ltd
Investor Presentation
Results of Meeting
AGM Presentation
AGM Chairman's Address
BioPartnering Europe Presentation
Investor Presentation
AGM - Notice of Meeting
Annual Report
Full Year Results Commentary
Appendix 4E
Licenses LAIV to Serum Institute of India
Replaces Nobilon as Licensor to WHO
Regains LAIV technology rights
Half Year Results
US$0.25m Royalties Received on Nasovac Sales
US & China Patents Granted for BDM-I
Merck/Schering-Plough Update
Results of Annual General Meeting
AGM Presentations
Chairman's Address to Shareholders
Placement of $1m of Rights Issue Shortfall
Appointment of Projects Manager
FDA Grants Orphan Drug Status to BDM-E
LAIV Featured at International Conference
Annual Report
Financial Results
LAIV Launched in India
